is a Senior Principal with Kacvinsky Daisak Bluni PLLC. He provides KDB clients an innovative and progressive approach to product-oriented counsel on all issues related to intellectual property. Scott’s senior law firm, in-house, and patent examiner positions provide clients and colleagues with a strategic and trusted perspective on intellectual property law. He has been recognized by Chambers USA as having “fantastic practical business instincts as well as strong legal skills”.
The latest ruling involving patent eligibility of medical diagnostics comes from Chief Judge Connolly of the United States District Court for the District of Delaware in a consolidated case brought by CareDx, Inc. and the Board of Trustees of the Leland Stanford Junior University against Natera, Inc. (Civil Action No. 19-0567-CFC-CJB) and Eurofins Viracor, Inc. (Civil Action No. 19-1804-CFC-CJB). After initially denying the Defendants’ motions for summary judgment of invalidity of the asserted patents under 35 U.S.C. §101 in December 2020, the Court then later denied certification motions for interlocutory appeal and instead ruled sua sponte to reconsider its own denial of summary judgment. Following an evidentiary hearing during which expert testimony was heard, the Court reversed its previous ruling to find all claims of the asserted patents invalid as a matter of law under §101.